Skip to the lineages
Regenerative Medicine

What Are Orthobiologics, and How Are They Classified?

Published November 16, 2026

Protocol: 6 steps in this guide
  1. What falls under the orthobiologic umbrella
  2. Blood-derived preparations versus cellular preparations
  3. Cell and tissue sourcing distinctions
  4. Processing and regulation are separate dimensions
  5. Where clinical evidence differs by joint or tissue
  6. How to assess an advertised orthobiologic product

“Orthobiologic” is not the name of one treatment. In this guide it means a family of biologic materials offered in musculoskeletal care: preparations made from a patient’s own blood, concentrates made from bone marrow or fat, and products made from donated birth tissue. Each class has a different starting material, a different processing step and a different regulatory question, and evidence that one class helps one condition says nothing about the others.

The U.S. Food and Drug Administration uses the word too. Its patient and consumer notice on regenerative medicine therapies lists “ortho-biologics” alongside stem cells, stromal vascular fraction, cord blood, amniotic fluid, Wharton’s jelly and exosomes as unapproved products that are being broadly marketed, and says such products require FDA licensure or approval to be marketed. That notice is a warning about marketing, not a classification of every procedure, so the label on an advertisement tells you very little until you know which class the product belongs to.

What falls under the orthobiologic umbrella

A practical way to sort these materials is by what goes into the syringe:

  • Blood-derived preparations. Platelet-rich plasma (PRP) is the best known. Blood is drawn from the patient and spun to concentrate platelets.
  • Concentrated cells from the patient’s own tissue. Bone marrow aspirate concentrate (BMAC) is made from the patient’s bone marrow. Stromal vascular fraction (SVF) comes from fat, which FDA describes as “fat-derived cells.”
  • Donor birth-tissue products. Cord blood, amniotic fluid and Wharton’s jelly products come from another person’s birth tissue.
  • Exosome products. Exosomes are sold as a product in their own right and appear on the same FDA warning list.

The grid below summarizes the questions a reader should ask of each class. It is an editorial comparison built from the sources linked in this article, not an FDA classification.

Class Starting material Living cells in the product? Processing step that defines it First regulatory question
PRP Patient's own blood Platelets, plus white blood cells in some preparations Centrifugation to concentrate platelets Which device prepared it, and for what use?
BMAC Patient's own bone marrow Mixed marrow cells; counts vary widely between studies Aspiration and concentration Does it meet the narrow bone marrow exclusion?
SVF Patient's own fat Fat-derived cells Cell isolation from fat tissue How much manipulation, and for what use?
Cord blood, amniotic or Wharton's jelly products Another person's birth tissue Not established by the label Varies by product; ask the seller Is this exact product licensed for this use?
Exosomes Varies by product; ask the seller Not cells; see the exosome guide linked below Varies by product; ask the seller Is this exact product licensed for this use?

Exosomes are covered in what exosomes are and how they differ from living cells.

Blood-derived preparations versus cellular preparations

The American Academy of Orthopaedic Surgeons explains on its patient page on platelet-rich plasma that blood is drawn from the patient, the platelets are separated and concentrated by centrifugation, and the concentration of platelets can be 5 to 10 times greater than usual. AAOS also distinguishes leukocyte-rich from leukocyte-poor PRP by white blood cell content and states that their relative effectiveness has not yet been determined. The two mixtures are compared in how leukocyte-rich and leukocyte-poor PRP differ, and the preparation steps are covered in how platelet-rich plasma is made from a blood sample.

Preparations enriched in alpha-2-macroglobulin (A2M), a large plasma protein found in PRP, are another blood-derived example; a 2024 randomized trial in knee osteoarthritis (Thompson and colleagues, Bulletin of the Hospital for Joint Diseases) compared an A2M-rich PRP concentrate with conventional PRP and a corticosteroid. These preparations are still made from blood, not from tissue cells, and the biology of the protein is explained in what alpha-2-macroglobulin does in the body.

The practical line is simple. A blood-derived preparation concentrates what is already circulating in the patient’s blood. A cellular preparation concentrates or isolates cells from a tissue. Calling either one a “stem cell treatment” requires evidence about what is actually in the syringe.

Cell and tissue sourcing distinctions

Two questions separate the cellular classes: where the cells come from, and what kind of cells they are.

Source. Autologous products come from the patient. Allogeneic products come from a donor. FDA’s notice makes clear that the warning covers both: unapproved products “whether recovered from your own body or another person’s body.”

Cell type. The National Institute of General Medical Sciences explains in What Are Stem Cells? that embryonic stem cells are pluripotent, while somatic (adult) stem cells are multipotent and “can only differentiate into a small subset of cell types.” A product made from adult tissue is therefore not a source of embryonic-type cells, whatever the marketing says.

Bone marrow concentrate shows why the cell-type question matters. A 2025 systematic review of BMAC harvest sites pooled 15 nonrandomized prospective studies with 583 patients. Total nucleated cell counts ranged from 0.1 to 502 million cells per milliliter in axial-skeleton harvests and from 0.1 to 87 million per milliliter in appendicular harvests, with no significant difference between the two site groups. That review measured cell yield in the lab, not patient outcomes. A separate 2019 systematic review in Arthroscopy (Cavinatto and colleagues) reported that cells present in BMAC did not meet the International Society for Cell Therapy criteria to be characterized as mesenchymal stem cells. A concentrate of mixed marrow cells is therefore not a measured dose of stem cells. The full picture is in what bone marrow aspirate concentrate contains, and fat-derived cells are covered in what stromal vascular fraction from adipose tissue is.

Processing and regulation are separate dimensions

Two products can start from the same tissue and end up in different regulatory positions because of how they are processed and what they are used for.

FDA’s page on its framework for the regulation of regenerative medicine products describes a “risk-based, flexible regulatory framework” and a set of final guidance documents for human cells, tissues and cellular and tissue-based products (HCT/Ps), including guidance on minimal manipulation and homologous use. Both are tests applied to a specific product and its intended use, not to a product category.

The federal definition of HCT/Ps in 21 CFR 1271.3(d) also lists items that are not HCT/Ps, among them whole blood, blood components and blood derivative products subject to the listed blood-product rules, and minimally manipulated bone marrow for homologous use that is not combined with another article except permitted agents. Those exclusions describe which rules apply. They do not mean a product is approved, safe or effective for a joint, and each condition in the text has to be met for the exclusion to apply.

In practice, “FDA-registered,” “made from your own cells” and “FDA-approved” are three different statements. FDA’s notice says that listing a product on ClinicalTrials.gov, or a firm registering with FDA, “does not mean the product is legally marketed.” How to check a named product is explained in how to tell whether a regenerative medicine product is FDA-approved, and the rules for cell products sold for joint pain are covered in how the FDA regulates stem cell products promoted for joint pain.

Where clinical evidence differs by joint or tissue

Because the classes differ, their evidence differs too, and so does the evidence for one class across different conditions. AAOS’s PRP page describes this unevenness for PRP alone: it reports research support for some chronic tendon problems and for low- to moderate-grade knee osteoarthritis, “little or no benefit” when PRP is used in rotator cuff repair surgery or ACL surgery, and “no significant benefit” so far for fractures.

Smaller joints have their own, smaller evidence base, as in what research says about PRP for thumb base osteoarthritis. Newer trials can also disagree with older summaries. A 2026 meta-analysis of placebo-controlled trials in tennis elbow found no significant pain or function benefit for PRP, which is covered in whether PRP is effective for tennis elbow. Knee arthritis evidence, including conflicting guidelines, is reviewed in what the evidence says about PRP for knee osteoarthritis.

The rule that follows is narrow: evidence attaches to a specific preparation, a specific condition, a specific comparator and a specific follow-up period. It does not transfer to the whole orthobiologic family.

How to assess an advertised orthobiologic product

When a clinic offers an orthobiologic injection, five questions turn a marketing label into something you can check:

  1. What exactly is it? Ask for the starting material (blood, marrow, fat, donor tissue) and whether the product is made on site from your own tissue or comes from a donor or manufacturer.
  2. How is it prepared? Ask which device or process is used and what the final product contains, including any cell counts the clinic actually measures.
  3. What is its regulatory status for this use? Ask for the product’s exact name and whether it is licensed or approved for the condition being treated, not just whether the company is “registered.”
  4. What evidence applies to your condition? Ask which studies tested this class of product in your joint or tissue, against what comparator, and for how long.
  5. What are the risks and costs? AAOS reports that the risks associated with PRP appear minimal but include increased pain at the injection site, and that few insurance plans provide even partial reimbursement. FDA reports blindness, tumor formation and infections linked to unapproved regenerative products. Ask what applies to the product you are being offered.

Claims that a product “regrows cartilage” deserve particular care, because pain relief and tissue restoration are different outcomes; how to recognize unsupported claims about cartilage regeneration walks through that check. For the unapproved stem cell, exosome and similar products its notice lists, FDA warns that if you are charged for them or offered them outside a clinical trial, you “are likely being deceived and offered a product illegally,” and it invites questions at ocod@fda.hhs.gov. That warning concerns those products; it is not a ruling on every orthobiologic procedure, such as PRP prepared from your own blood, whose status depends on the product, the device and the use.

Knowing the class of a product narrows the questions; whether any orthobiologic suits a specific injury remains a decision for a qualified clinician who has examined you.

An orthobiologic label describes where a product comes from, not whether it works: the class, the exact product, its regulatory status for your use and the evidence for your condition all have to be checked separately.

Cells linked to this one

This guide leads on to

Guides that lead here

Lineage A: Regenerative Biology

What readers added

Add a remark

Your email address will not be published. Required fields are marked *